DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical Affairs and Scientific Communications (DIA MASC) forum I attended in March 2025, along with a focus on how we can utilize these tools to achieve impactful, engaging, and scientifically accurate communications that resonate with healthcare providers (HCPs) and patients. Along…...
Read More

Top Stories

Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...
AI in Medical Affairs & Medical Communications

Science, AI, and Human Ingenuity Converge to

Today, we're witnessing an unprecedented convergence of...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
A summary of journal articles authored by the Cactus Life Sciences team

Our Journal Publication Showcase

A summary of journal articles authored by the Cactus Life Sciences team...
Trends in publication review of articles

Review Article Publication Trends

This poster was presented by representatives from Cactus Life Sciences at the 11th Annual Meeting...
EU MDR Whitepaper

EU MDR: Increasing Expectations for Clinical Evidence

While the global medical devices industry is closely watching how the European Union (EU) Medical...
A fireside chat on how MedTech leaders are called to respond to EU-MDR

Fireside Chat Part 1: How MedTech Leaders Are Called to Respond to EU MDR

A fireside chat on how MedTech leaders are called to respond to EU-MDR...
International publication guidelines in Asia

Awareness of International Publication Guidelines in Asia

This poster presents the results of an analysis of how familiar Asian authors are with...
FDA social media usage guidelines

US FDA (Food And Drug Administration) Social Medial Usage Guidelines: Compliance for Pharma Companies

This poster presents results of an analysis of trends in adherence of pharmaceutical companies to...

Learn more ABOUT our company.